First Bancorp (NASDAQ:FBNC) reported quarterly earnings of $0.71 per share. This is a 11.25 percent decrease over earnings of $0.8 per share from the same period last year.
Verve Therapeutics Announced VERVE-101 Awarded Innovation Passport By UK MHRA For Treatment Of Heterozygous Familial Hypercholesterolemia
Verve Therapeutics, Inc. today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK).
